Rs 2,000 crore drug haul leads to bad blood in FDA
Based on the findings, seven officials to be charged under Section 59 of the NDPS Act, applicable to an officer who stops performing his roles or withdraws from duties.

The move has created ripples in the organization, dividing the drug regulatory body like never before.
In April this year, the Thane crime branch busted what they claimed was one of the country's biggest drug rackets. They found that the controlled substance ephedrine and its salts were stolen out of the premises of Avon Life Sciences, Solapur, and sold in the illegal drug market after purification. The FDA's vigilance department had subsequently carried out three inspections of the factory and found 28 violations under the NDPS as well as the Drug and Cosmetics Act.
Additionally, the vigilance team under joint commissioner (vigilance) Harish Baijal indicted the FDA officials—right from the drug inspectors to joint commissioners—on various counts.
Baijal's team, comprising assistant commissoner Madhuri Pawar and drugs inspectors Sachin Kamle and Abasaheb Raskar, found that the officials were negligent of not carrying out timely inspections of Avon premises, granting fresh licences without thorough record-checking and failing to prosecute the company for breaches. Around 21,500 kg of DL ephedrine base was illegally sold to two smaller companies without permission.
Based on the findings, Baijal recommended that seven officials be charged under Section 59 of the NDPS Act, applicable to an officer who stops performing his roles or withdraws from duties. If charged, the FDA officials could face a jail term of up to one year. The report said there was a total failure of regulatory mechanism in narcotics control and blamed officials for facilitating commission of offence by drug dealers.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.